Topics

2012/07/09

  • available-technologies
  • Biotechnology

Some of our compounds, which have been developed as VCP inhibitors (no,3027), showed strong neuroprotective effects for retinal neuronal cells, including ganglion cells and photoreceptor cells, each suffered in glaucoma and retinal pigmentary degenerations, respectively. Oral daily administration of these compounds to mouse models of retinal disorders, namely GLAST knockout mouse as well as DBA/2J mouse or rd10 mouse, showed significant protection of ganglion cells or photoreceptor cells, respectively, from cell death during treated periods, e.g. up to 8 months for GLAST knockout mouse, without showing any apparent side effects.

Contact

Please use this form to contact the SACI.However, the response may be sent from a
department/division other than the SACI, such as from another division within
the university or from an affiliated company outside the university.